Medtronic PLC $MDT Shares Acquired by Natixis Advisors LLC

Key Points

• Natixis Advisors increased its stake in Medtronic by 10.1% to 2,617,776 shares (about 0.20% of the company), valuing its holding at roughly $249.3 million, while institutional investors now own about 82.06% of the stock.
• Medtronic beat quarterly estimates with $1.36 EPS (vs. $1.34 expected) and $9.02 billion in revenue, set FY2026 guidance of $5.62–$5.66 EPS, yet the stock traded lower amid mixed market reaction.
• Dividend and MiniMed update: Medtronic declared a $0.71 quarterly dividend (annualized $2.84, ~3.1% yield; ex-dividend Mar 27), while its diabetes unit MiniMed raised $560M in an IPO priced at $20 but debuted below the offering and Medtronic retains ~90% ownership, tempering near‑term value‑unlock expectations.

Natixis Advisors LLC lifted its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 10.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,617,776 shares of the medical technology company's stock after purchasing an additional 240,545 shares during the period. Natixis Advisors LLC owned approximately 0.20% of Medtronic worth $249,317,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MDT. Norges Bank acquired a new stake in Medtronic during the 2nd quarter worth about $1,432,698,000. Barclays PLC lifted its position in shares of Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock valued at $650,604,000 after acquiring an additional 3,492,192 shares in the last quarter. Guinness Asset Management LTD purchased a new stake in shares of Medtronic in the 3rd quarter valued at approximately $275,556,000. Vanguard Group Inc. boosted its stake in Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company's stock worth $11,062,693,000 after purchasing an additional 1,895,165 shares during the period. Finally, Magellan Asset Management Ltd acquired a new position in Medtronic in the 3rd quarter worth approximately $126,347,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Wall Street Analyst Weigh In

MDT has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Medtronic from $105.00 to $100.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 18th. CICC Research started coverage on Medtronic in a research report on Friday, January 30th. They issued an "outperform" rating for the company. Wells Fargo & Company assumed coverage on Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 price target on the stock. TD Cowen reissued a "buy" rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Weiss Ratings reissued a "buy (b-)" rating on shares of Medtronic in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.74.

Medtronic Stock Down 2.3%

Medtronic stock opened at $90.83 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The firm's fifty day simple moving average is $98.69 and its 200-day simple moving average is $96.99. The company has a market capitalization of $116.61 billion, a P/E ratio of 25.30, a P/E/G ratio of 2.28 and a beta of 0.71.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio is 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved quarterly cash dividend of $0.71 per share (annualized yield ~3.1%), supporting income investors and signaling confidence in cash flow. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Product/market progress in diabetes care with the MiniMed Go Smart MDI system launch in Europe, strengthening Medtronic’s connected diabetes portfolio and long‑term growth potential in CGM/smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Operational tech wins: updates on a Tempus clinical trial and expanded patient‑monitoring alliance with GE HealthCare, which could broaden distribution and adoption of Medtronic devices over time. Digital Alerts and Heart Valves: What Medtronic Investors Should Watch in New Tempus Trial Medtronic, GE HealthCare expand patient monitoring alliance
• Neutral Sentiment: MiniMed priced its IPO at $20 per share and raised about $560M, giving the standalone diabetes unit initial capital and a public valuation backdrop. This is a financing/structuring move that could be positive long term but is mixed near term. Medtronic's diabetes unit MiniMed raises $560 million in US IPO
• Negative Sentiment: MiniMed’s Nasdaq debut opened below the offering price (shares down ~4.8% on debut), which pressured sentiment toward the spinoff and Medtronic’s value‑unlock story — investors reacted to a softer than expected market reception. Medtronic's diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
• Negative Sentiment: Medtronic retains ~90% ownership of MiniMed after the IPO, limiting immediate capital release and potential near‑term accretion from the spinoff — this reduces the perceived benefit of the listing for MDT shareholders today. MiniMed (MMED) IPO Falls Flat as Medtronic (MDT) Spinoff Debuts Below Price

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.26% of the company's stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.